Anavex to Present on Sigma-1 Receptors at the World Orphan Drug Congress and to Reveal New Epilepsy Data at Antiepileptic Drug Trials XIII Conference

NEW YORK, NY – April 23, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the World Orphan Drug Congress on Thursday, April 23, 2015 at 11:10 a.m. ET at The Washington Hilton in Washington, DC. In a…

Anavex Encouraged by New Scientific Data Revealing Positive Role of Sigma-1 Receptors in Brain Injuries

Report Further Validates Therapeutic Application of Proprietary Anavex Compounds in Multiple Neurological Diseases NEW YORK, NY – April 7, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) is encouraged by the findings of a new report in the latest issue of peer-reviewed scientific journal Neuroscience Letters. The study demonstrates for the first time…

Anavex Presents Positive Results for Both ANAVEX 2-73 and ANAVEX 3-71 in Alzheimer’s Models at 2015 AD/PD™ Conference

ANAVEX 2-73 strong reversal of memory impairment in Alzheimer’s disease model ANAVEX 3-71 strong reversal of synaptic loss in Alzheimer’s disease models NEW YORK, NY – March 23, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s and other central nervous system…

Anavex Appoints Epilepsy and Clinical Trial Methodology Expert to Scientific Advisory Board

NEW YORK, NY –March 12, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of Jacqueline French, MD, FAAN, to the Company’s Scientific Advisory Board.…

Anavex to Present at Sigma-1 Receptors Symposium

NEW YORK, NY – March 10, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present…

Anavex Appoints Scientific Advisory Board Member with Expertise in Protein Misfolding Neurodegenerative Diseases

NEW YORK, NY –March 5, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of Corinne Lasmézas, DVM, PhD, to the Company’s Scientific Advisory Board.…